ASH News Daily 2013 - Day 2 - (Page B-28)

preventive dentistry prior to treatment with bisphosphonate dental procedures, if possible, as recovery may be prolong bisphosphonate therapy, dental surgery may exacerbate th procedures, there are no data available to suggest wheth treatment reduces the risk of ONJ. A causal relationship be (These acknowledgments reflecthas not been established. Clinical judgment of the treating ph contributions made prior to October 22, 2013.) plan of each patient based on individual benefit/risk assessm ZOMETA should not be used during pregnancy. Women of ch to avoid becoming pregnant. ASH Bridge grAnt ProgrAm If the patient becomes pregnan The Society thanks the following companies who supported this program in apprised of the potential harm this drug, the patient should be 2013: In postmarketing experience, severe and occasionally incapa has been reported in patients taking bisphosphonates includ symptoms develop, and a subset of patients had recurrenc the same drug or another bisphosphonate. There have bee sensitive patients receiving bisphosphonates. Insufficient data exist on how to safely use ZOMETA in HCM Acute-phase reaction symptoms can occur in HCM patient with ZOMETA vs. 33% with pamidronate). Patients may oc chills, flushing, bone pain and/or arthralgias and myalgias). The About the Bridge Grant Award * ASH membership is causality, with ZOMETA clinical trials, regardless of required at the time of applica-4 mg (n= tion to the anemia (22%), dyspnea (22%), This year and for the next two years, ASH's constipation (27%),Bridge Grant program and throughout diarrhe Bridge the award period. Grant program will provide at least 30 one-year cancer (16%), insomnia (15%), vomiting (14%), anxiety (14% awards annually, in the amount of $100,000 each, to * There are two award cycles per year. (13%), confusion (13%), agitation (13%), moniliasis (12% ASH members who applied for an NIH R01 grant or * The Society is currently seeking support from indipain (12%), hypotension (11%), and hypomagnesemia (11% vidual and corporate donors in order to provide adequivalent but were denied funding due to budget cut(5-10% frequency) occurring in greater incidence with ZOME ditional awards. backs. The long-term goal of the award is to help sustain leg edema, mucositis, dysphagia, granulocytopenia, throm recipients' research and contribute to their retention in Award dehydration, arthralgias, headache and somnol hematology investigation. hypocalcemia,Timeline Fourth Round been infrequently reported. Application deadline: Additional Details The most common adverse events (≥15%) in bone metastas * From 2013 through 2015, ASH will award 90 ASH April 1, 2014 4 mg Applicant were as follows: bone pain (55%), nausea members (30 per year) with $100,000 Bridge Grants, (n=1031) notification of acceptance: vomiting (32%), constipation (31%), dyspnea (27%), diarrh Mid-to-late June 2014 for a $9 million total investment. (22%), cough (22%), arthralgia (21%), lower-limb edema (21 (19%), dizziness (excluding vertigo) (18%), insomnia (16%), de (15%). Patients should also be made aware of the potential f ASH trAnSlAtionAl reSeArcH trAining in HemAtology Ocular adverse events may occur with bisphosphonates, in The Society thanks the following companies who supported this program in 2013: conjunctivitis, iritis, and orbital inflammation including orbital some cases, symptoms resolved with topical steroids. Caution is advised when bisphosphonates, including ZOMET and potentially nephrotoxic drugs. Patients with multiple myeloma and bone metastases due supplement of 500 mg and a multiple vitamin containing 400 2013 ASH Award Supporters References: 1. Rosen LS, Gordon D, Kaminski M, et al; Zoledronic Acid Breast Cancer compared with pamidronate disodium in the treatment of skeletal complications in pa blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744. 2. Wu EQ, Bensim patterns associated with early vs. delayed zoledronic acid therapy in multiple myelom et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Pr Please see full Prescribing Information. Please see brief summary of full Prescribing Information on the © 2011 Novartis September 20

Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 2

Table of Contents

ASH News Daily 2013 - Day 2

https://www.nxtbookmedia.com